Abbott Laboratories news
The WiseView Research desk's stories that name Abbott Laboratories, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The ABT page →
- CongressPete Sessions sold $50,001 - $100,000 of ABT
- HeadlineIs Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
- HeadlineIs Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
- HeadlineAbbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead
- HeadlineThis Dividend King Just Announced Great News for Investors
- HeadlineAbbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- HeadlineAbbott Laboratories: A New Growth Story Takes Shape
- HeadlineAbbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- HeadlineAbbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook
- HeadlineCologuard Is Working—So Why Isn't Abbott Stock?
- HeadlineAbbott: 3 Key Takeaways for Long-Term Investors
- HeadlineAbbott Q3: Nutrition Spin-Out, Narrowed Guidance Rocks Stock; For Now, At Least
- HeadlineNasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
- HeadlineAbbott Laboratories (ABT) Q3 2026 Earnings Call Transcript
- HeadlineAbbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition Business Spin-Off
- HeadlineWhat Abbott Laboratories (ABT) Said on Its Q3 Earnings Call
- HeadlineABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
- HeadlineAbbott (ABT) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- HeadlineAbbott (ABT) Misses Q3 Earnings Estimates
- HeadlineAbbott to Carve Out Nutrition Business Into Independent Company
- HeadlineAbbott lowers 2026 sales growth forecast on medical device weakness
- HeadlineAbbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
- HeadlineAbbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
- HeadlineHow To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings
- Headline2 Industries Beyond AI With Long-Term Demand Drivers for 2027
- HeadlineCountdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Headline3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades
- HeadlineShould You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?
- HeadlineAbbott (ABT) Gains As Market Dips: What You Should Know
- CongressGilbert Cisneros bought $1,001 - $15,000 of ABT
- HeadlineHistory Says Abbott Stock Could More Than Double by 2036. Here's Why I Just Added It to My Portfolio.
- CongressRo Khanna bought $1,001 - $15,000 of ABT
- HeadlineIs It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
- HeadlineAbbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- HeadlineAbbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- HeadlineThis Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- HeadlineAbbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
- HeadlineAbbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- HeadlineAbbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
- HeadlineAbbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- HeadlineAbbott hosts conference call for third-quarter earnings
- Headline3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth
- CongressRick Allen sold $15,001 - $50,000 of ABT
- CongressMike Kelly sold $1,001 - $15,000 of ABT
- CongressRick Larsen sold $1,001 - $15,000 of ABT
- CongressRo Khanna bought $1,001 - $15,000 of ABT
- CongressGilbert Cisneros bought $1,001 - $15,000 of ABT
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.